Advertisement
James A. Bianco, M.D., President and CEO of CTI said, "Dick brings awealth of entrepreneurial and drug development experience in thebiopharmaceutical industry to CTI's board. We look forward to his input as wemove toward the commercialization of pixantrone, XYOTAX(TM), andBrostallicin."
Advertisement
Love has worked in the industry for more than 40 years, including 27 yearsof bioscience leadership experience. He founded two biopharmaceuticalcompanies, Triton Biosciences Inc. and ILEX Oncology, Inc. Love was CEO atboth companies, and leading the clinical development teams in the creation offour drugs currently in use -- Betaseron(R), a treatment for multiplesclerosis, two treatments for chronic lymphocytic leukemia, Fludara(R) andCAMPATH(R), and Clolar(R), a treatment for acute leukemias.
"We are very excited to have Dick join CTI's board, and look forward toutilizing his industry expertise," said Phillip M. Nudelman, Ph.D., Chairmanof the Board of CTI. "His leadership experience makes him a great addition tothe board."
In addition to CTI, Love is currently Chairman of the Board of ImaRxTherapeutics, and he serves on the boards of PAREXEL International, andMolecular Profiling Institute. He previously served on the board of XilasMedical, Inc. Love has been active with various non-profit organizations aswell, serving on the boards of the Cancer Therapy and Research Center (CTRC)in San Antonio, TX, and the Translation Genomics Research Institute (TGen) inPhoenix, AZ.
"I am thrilled to join the CTI board and to have the opportunity to helpthe company reach its goal of making cancer more treatable," said Love. "I amfully committed to the Company's mission and look forward to contributing myexperience to the development of both the Company and its drug candidates."
Mr. Love holds Bachelors and Masters of Science degrees in ChemicalEngineering from the Virginia Polytechnic Institute.
In addition to Love, CTI's Board of Directors includes Phillip M.Nudelman, Ph.D., Chairman of the Board, President and Chief Executive of TheHope Heart Institute and former President and CEO of Group Health Cooperative;Frederick W. Telling, Ph.D., former Corporate Officer and Vice President ofCorporate Policy and Strategic Management for Pfizer Inc.; Vartan Gregorian,Ph.D., President of Carnegie Corporation of New York; Mary O. Mundinger, Dr.PH, Dean and Professor, School of Nursing and Associate Dean, Faculty ofMedicine, Columbia University; John H. Bauer, former EVP of Finance forNintendo of America, Inc.; James A. Bianco, M.D., President and CEO of CTI;and Jack W. Singer, M.D., Chief Medical Officer of CTI.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed todeveloping an integrated portfolio of oncology products aimed at making cancermore treatable. For additional information, please visithttp://www.cticseattle.com.Media Contact: Dan Eramian T: 206.272.4343 C: 206.854.1200 Susan Callahan T: 206.272.4472 F: 206.272.4434 Lindsey Jesch T: 206.272.4347 E: [email protected] http://www.cticseattle.com/media.htm Investors Contact: Leah Grant T: 206.282.7100 F: 206.272.4434 E: [email protected] http://www.cticseattle.com/investors.htm
SOURCE Cell Therapeutics, Inc.
